Marshall Wace
PALI icon

Marshall Wace’s Palisade Bio PALI Stock Holding History

Marshall Wace’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$833K Sell
398,790
-2,355,613
-86% -$4.64M ﹤0.01% 2293
2026
Q1 		$4.82M Buy
+2,754,403
New +$5.01M ﹤0.01% 1324

Other funds holding PALI

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Marshall Wace's PALI Position: Q2 2026 in Review

Marshall Wace reduced its Palisade Bio (PALI) stake by 86% in Q2 2026, selling an estimated $4.64M and leaving 398,790 shares worth $833K. The position accounts for ﹤0.01% of the portfolio, ranked #2293.

Marshall Wace first reported a position in PALI in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.82M in Q1 2026. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

  • Marshall Wace held 398,790 shares of Palisade Bio worth $833K as of Q2 2026.
  • Marshall Wace sold 2,355,613 Palisade Bio shares in Q2 2026, an estimated $4.64M.
  • Palisade Bio made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2293 holding.
  • Marshall Wace first reported a position in Palisade Bio in Q1 2026 and has held it in 2 quarters since.
  • Marshall Wace's Palisade Bio position peaked at $4.82M in Q1 2026.
  • 124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.